Form 4: Monte Rosa Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Kimberly Blackwell acquired stock options for 22,100 shares of Monte Rosa Therapeutics, Inc. (GLUE) on June 12, 2024.
Summary
- On June 12, 2024, Kimberly Blackwell, a director of Monte Rosa Therapeutics, Inc. (GLUE), acquired stock options for 22,100 shares.
- The exercise price of these options is $4.16 per share.
- The options vest fully on the earlier of June 12, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
- The options expire on June 12, 2034.
- Following the transaction, Blackwell directly owns options for 22,100 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of transaction: Kimberly Blackwell acquired stock options. |
| 06/12/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 06/12/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.